Physician profile
Marlene Herrera
NPI 1477195527
$4,977.48
in general payments reported to CMS, 2019-2025
29 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $532 · 2023: $974 · 2024: $1,556 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,094.23 | 2021-2025 | |
| Lilly USA, LLC | $596.82 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $482.93 | 2023-2025 | |
| Amgen INC. | $466.37 | 2021-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $435.57 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $420.74 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $401.32 | 2023-2025 | |
| Abiomed | $152.99 | 2024 | Impella |
| Antares Pharma, INC. | $128.88 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $87.48 | 2022-2023 | Trelegy Ellipta, Arexvy |
| Tolmar, INC. | $79.96 | 2023-2025 | Jatenzo |
| Axsome Therapeutics, INC. | $72.82 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $68.59 | 2022-2024 | Trintellix |
| Exact Sciences Corporation | $54.58 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $48.42 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $47.38 | 2024-2025 | Oxlumo |
| Merck Sharp & Dohme LLC | $37.76 | 2025 | Gardasil 9, Capvaxive |
| Ibsa Pharma INC. | $36.94 | 2024 | Licart, Tirosint, Flector |
| Idorsia Pharmaceuticals US INC | $35.26 | 2022-2024 | Quviviq |
| Esperion Therapeutics, INC. | $34.40 | 2022-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.79 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $31.37 | 2022 | |
| Acerus Pharmaceuticals Corporation | $28.42 | 2022 | |
| Boston Scientific Corporation | $26.04 | 2024 | Ams 700 |
| Organogenesis INC. | $21.65 | 2023 | Puraply |
| Novartis Pharmaceuticals Corporation | $19.48 | 2025 | |
| Convatec INC. | $14.93 | 2023 | |
| Phathom Pharmaceuticals, INC. | $10.51 | 2025 | Voquezna |
| Organon LLC | $9.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.